S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'

ICON Public (ICLR) Stock Price, News & Analysis

$335.95
+6.45 (+1.96%)
(As of 03/28/2024 ET)
Today's Range
$327.77
$336.74
50-Day Range
$259.57
$340.00
52-Week Range
$181.92
$344.77
Volume
499,746 shs
Average Volume
488,617 shs
Market Capitalization
$27.72 billion
P/E Ratio
45.52
Dividend Yield
N/A
Price Target
$312.64

ICON Public MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6.9% Downside
$312.64 Price Target
Short Interest
Healthy
1.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of ICON Public in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.35%
From $14.40 to $16.61 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.39 out of 5 stars

Medical Sector

400th out of 939 stocks

Commercial Physical Research Industry

5th out of 11 stocks

ICLR stock logo

About ICON Public Stock (NASDAQ:ICLR)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

ICLR Stock Price History

ICLR Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
ICON Plc
ICLR Apr 2024 430.000 put
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
ICON plc to Present at Upcoming Investor Conferences
ICON Full Year 2023 Earnings: EPS Beats Expectations
Icon PLC (ICLR) Q4 Earnings Surpass Estimates
ICON Reports Fourth Quarter and Full Year 2023 Results
ICON Reports Fourth Quarter and Full Year 2023 Results
ICLR Apr 2024 380.000 call
ICLR Jul 2024 330.000 call
Icon Stock (NASDAQ:ICLR) Insider Trades
29 of the Biggest Style Icons of All Time
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/29/2024
Next Earnings (Confirmed)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:ICLR
Employees
41,100
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$312.64
High Stock Price Target
$367.00
Low Stock Price Target
$220.00
Potential Upside/Downside
-6.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$612.34 million
Pretax Margin
7.69%

Debt

Sales & Book Value

Annual Sales
$8.12 billion
Cash Flow
$19.84 per share
Book Value
$112.02 per share

Miscellaneous

Free Float
46,197,000
Market Cap
$27.72 billion
Optionable
Optionable
Beta
1.15

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. John Climax Ph.D. (Age 71)
    Founder & Independent Non-Executive Director
    Comp: $90k
  • Mr. Brendan Brennan (Age 45)
    Chief Financial Officer
    Comp: $1.07M
  • Dr. Steven A. Cutler MBA (Age 64)
    Ph.D., CEO & Director
    Comp: $2.54M
  • Jonathan Andrew Curtain (Age 48)
    Senior Vice President of Corporate & Commercial Finance
  • Mr. Thomas N. O'Leary
    Chief Information Officer
  • Mr. Diarmaid Cunningham (Age 49)
    Chief Administrative Officer, General Counsel & Company Secretary
  • Ms. Niamh Murphy
    Director of Corporate Communications
  • Mr. David Green
    Vice President of Marketing
  • Mr. Joe Cronin
    Chief Human Resources Officer
  • Mr. Simon Holmes (Age 57)
    President of Corporate Investments & Partnerships

Should I Buy ICON Public Stock? ICLR Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ICON Public Limited:

  • ICON Public's stock price has been trading at a relatively high level, indicating positive market sentiment and potential for growth.
  • Recent analyst reports have given ICON Public a "buy" or "overweight" rating, suggesting confidence in the company's performance and future prospects.
  • ICON Public has a strong market capitalization of $27.61 billion, reflecting the company's stability and position in the industry.
  • With a beta of 1.15, ICON Public's stock is moderately volatile, offering opportunities for traders looking for fluctuations in price.
  • ICON Public's debt-to-equity ratio of 0.40 indicates a balanced financial structure, reducing the risk for investors concerned about leverage.

Cons

Investors should be bearish about investing in ICON Public Limited for these reasons:

  • ICON Public's stock has a relatively high PE ratio of 45.34, which may suggest the stock is overvalued compared to its earnings.
  • The PEG ratio of 1.56 for ICON Public indicates that the stock may be overpriced relative to its expected earnings growth rate.
  • While the stock has shown recent positive performance, there is always a risk of market downturns affecting the stock price in the short term.
  • ICON Public's 50-day moving average price of $282.80 may indicate short-term price volatility that could impact investor returns.
  • Investors should consider the company's exposure to regulatory changes in the healthcare and research industry, which could impact future profitability.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 24, 2024. Please send any questions or comments about these ICON Public pros and cons to contact@marketbeat.com.

ICLR Stock Analysis - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings
or view top-rated stocks.

What is ICON Public's stock price target for 2024?

8 equities research analysts have issued 12 month price objectives for ICON Public's shares. Their ICLR share price targets range from $220.00 to $367.00. On average, they predict the company's stock price to reach $312.64 in the next year. This suggests that the stock has a possible downside of 6.9%.
View analysts price targets for ICLR
or view top-rated stocks among Wall Street analysts.

How have ICLR shares performed in 2024?

ICON Public's stock was trading at $283.07 on January 1st, 2024. Since then, ICLR stock has increased by 18.7% and is now trading at $335.95.
View the best growth stocks for 2024 here
.

When is ICON Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our ICLR earnings forecast
.

How can I listen to ICON Public's earnings call?

ICON Public will be holding an earnings conference call on Thursday, April 25th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) released its quarterly earnings data on Wednesday, February, 21st. The medical research company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.13. The medical research company had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a net margin of 7.54% and a trailing twelve-month return on equity of 11.42%.

What guidance has ICON Public issued on next quarter's earnings?

ICON Public issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of 14.500-15.300 for the period, compared to the consensus estimate of 14.910. The company issued revenue guidance of $8.4 billion-$8.8 billion, compared to the consensus revenue estimate of $8.7 billion.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

Who are ICON Public's major shareholders?

ICON Public's stock is owned by many different institutional and retail investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.85%), TimesSquare Capital Management LLC (0.25%), State of Tennessee Treasury Department (0.19%), Kornitzer Capital Management Inc. KS (0.09%), Todd Asset Management LLC (0.06%) and Fayez Sarofim & Co (0.04%).

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ICON Public have any subsidiaries?
The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
This page (NASDAQ:ICLR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners